In Barcelona, Spain, on July 16, 2026, a major global healthcare company, Grifols, disclosed that they have begun dosing the initial patients in two distinct Phase 3 trials. The objective of these trials is to broaden the U.S. market approval for their key immunoglobulin medications. These include GAMUNEX ® -C, an intravenous immunoglobulin (IVIg), and XEMBIFY ®, a subcutaneous immunoglobulin (SCIg). Grifols is recognized as a top producer of plasma-derived medicines and is listed on the MCE under tickers GRF and GRF.P, as well as on the NASDAQ under ticker GRFS.